La Jolla Pharmaceutical Company
LJPC
LJPC was delisted on the 19th of August, 2022.
70 hedge funds and large institutions have $335M invested in La Jolla Pharmaceutical Company in 2016 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 34 increasing their positions, 15 reducing their positions, and 18 closing their positions.
154% more call options, than puts
Call options by funds: $1.49M | Put options by funds: $585K
127% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 15
13% less funds holding
Funds holding: 80 → 70 (-10)
23% less capital invested
Capital invested by funds: $434M → $335M (-$98.8M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
56% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
+$9.93M |
| 2 |
Jennison Associates
New York
|
+$4.43M |
| 3 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$3.51M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$3.21M |
| 5 |
RI
RTW Investments
New York
|
+$1.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$10.2M |
| 2 |
State Street
Boston,
Massachusetts
|
-$4.33M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.78M |
| 4 |
IHM
Iguana Healthcare Management
New York
|
-$2.97M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$2.24M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RFC
76
Russell Frank Company
Seattle,
Washington
| – | -$647K | -23,536 | Closed |
|
77
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$274K | -15,359 | Closed |
|
|
AL
78
Airain Ltd
St. Peter Port,
Guernsey
| – | -$363K | -13,451 | Closed |
|
|
CS
79
Credit Suisse
Zurich,
Switzerland
| – | -$344K | -12,768 | Closed |
|
|
CCM
80
Cadence Capital Management
Boston,
Massachusetts
| – | -$326K | -12,060 | Closed |
|
|
AI
81
Analytic Investors
Los Angeles,
California
| – | -$260K | -9,630 | Closed |
|
82
AllianceBernstein
Nashville,
Tennessee
| – | -$205K | -7,600 | Closed |
|
|
PAM
83
Panagora Asset Management
Boston,
Massachusetts
| – | -$90K | -3,335 | Closed |
|
84
BNP Paribas Financial Markets
Paris,
France
| – | -$79.8K | -2,956 | Closed |
|
85
Group One Trading
Chicago,
Illinois
| – | -$14.3K | -800 | -99% |
|
|
PCM
86
Prelude Capital Management
New York
| – | -$8K | -300 | Closed |
|
|
TRCT
87
Tower Research Capital (TRC)
New York
| – | -$6K | -230 | Closed |
|
|
IA
88
IFP Advisors
Tampa,
Florida
| – | -$4K | -150 | Closed |
|
LJPC Hedge Fund Activity: Q1 2016 in Review
70 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q1 2016, worth a combined $335M — down 23% from $434M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of LJPC and 8 opened new positions — a net loss of 10 holders — while 15 trimmed existing stakes and 34 added.
The largest buyer was Visium Asset Management, adding an estimated $9.93M. The largest seller was Avoro Capital Advisors, cutting an estimated $10.2M.
- 70 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q1 2016, down from 80 in Q4 2015.
- Funds reported $335M of La Jolla Pharmaceutical Company stock for Q1 2016, down 23% quarter-over-quarter.
- 8 funds opened new La Jolla Pharmaceutical Company positions in Q1 2016 and 18 closed out, a net change of -10 holders.
- The largest La Jolla Pharmaceutical Company buyer in Q1 2016 was Visium Asset Management, an estimated $9.93M added.
- The largest La Jolla Pharmaceutical Company seller in Q1 2016 was Avoro Capital Advisors, an estimated $10.2M sold.
Based on aggregated 13F filings for Q1 2016.